Spectrophotometric method development and validation for simultaneous estimation of Anagliptin and Metformin HCl BY Q - Absorption ratio method in synthetic mixture

Ruchi H. Majithia a, b, *, Dr. Akruti Khodadiya c, Vaibhav B. Patel a

a SAI Institute of Pharmacy, Ahmedabad, Gujarat, 380060, India
b C. U. Shah College of Pharmacy and Research, India
c C.U. Shah University, Wadhwan City, Gujarat, 363030, India

A R T I C L E   I N F O
Keywords:
Anagliptin (ANA)
Metformin HCl (MET)
Q - Absorption ratio method
Iso - Absorbptive point
Simultaneous estimation
Chemistry
Analytical chemistry
Spectroscopy
Inorganic chemistry
Organic chemistry
Pharmaceutical chemistry

A B S T R A C T
A simple, accurate, precise and economical Q - Absorption Ratio spectrophotometric method was developed and validated for estimation of Anagliptin and Metformin HCl in synthetic mixture. Anagliptin and Metformin HCl showed an iso-absorbptive point at 238 nm in distilled water. The second wavelength used was 233 nm which is λmax of Metformin HCl in distilled water. The concentration of the drugs was determined by using ratio of absorbance at iso-absorbptive point (λ1 = 238 nm) and at the λmax of Metformin HCl (λ2 = 233 nm). This method is linear for both drugs in range of 2–12 μg/mL at λ1 (R2 = 0.999) and at λ2 (R2 = 0.9998) for Anagliptin, and in the range of 5–30 μg/mL for Metformin HCl found at λ1 (R2 = 0.9995) and at λ2 (R2 = 0.9997). The % Recovery was 100.42–101.83 % of Anagliptin and 99.94–101.63 % of Metformin HCl by standard addition method. The LOD was found to be 0.0201 μg/mL and 0.262 μg/mL for Anagliptin at λ1 and λ2 respectively. The LOD was found to be 0.320 μg/mL and 0.167 μg/mL for Metformin HCl at λ1 and λ2 respectively. The LOQ was found to be 0.610 μg/mL and 0.794 μg/mL for Anagliptin at λ1 and λ2 respectively. The LOQ was found to be 0.972 μg/mL and 0.506 μg/mL for Metformin HCl at λ1 and λ2 respectively. The method was found to be precise as % RSD was less than 2.00 in Repeatability, Interday and Intraday precision for Anagliptin and Metformin HCl. The % assay of analyte drugs in synthetic mixture was found to be 100.601 % of Anagliptin and 100.206 % of Metformin HCl which showed good applicability of the developed method.

1. Introduction

Anagliptin, in form of Suiny® (100 mg tablets) is new drug formulation for type 2 diabetes therapy approved by the Japanese regulatory authority in 2014 [1]. Anagliptin, chemically N-[2-][(2S)-2-Cyanopyrrolodin-1-yl]-2-oxoethyl] amino]-2-methylpropyl]-2-methylpyrazolo [1, 5-α] pyrimidine-6-carboxamide (Figure 1) is a Dipeptidyl Peptidase 4 (DPP 4) inhibitor which is used in treatment of type 2 NIDDM [2]. Dipeptidyl Peptidase 4 enzyme breaks down the incretins GLP-1 gastrointestinal hormones released in response to a meal. By preventing GLP-1 inactivation, they are able to increase the secretion of insulin and suppress the release of glucagon by the alpha cells of the pancreas. This drives blood glucose levels towards normal level [3, 4]. This drug is not official in any of the pharmacopeia. Anagliptin is a very effective pill with minimum risk profile for type 2 diabetes mellitus and longer duration of action for treatment of type 2 non-insulin dependent diabetes mellitus disease [5]. A literature survey revealed that few methods are reported for determination of ANA, either alone or in combination [6], by spectrophotometric [7, 8, 9], HPLC [10], LC/MS [11].

Metformin is chemically a 1-Carboximidamide-N, N-Dimethylmethanimidamide [12] (Figure 2) and has pharmacological action based on Biguanides category [13, 14]. It suppresses hepatic gluconeogenesis and glucose output from liver. This is the major action responsible for lowering blood glucose in diabetics. It is official in IP [15], BP [16], and USP [17]. Literature review reveals that many spectrophotometric [18, 19], HPLC [20, 21], HPTLC [22] methods are reported for determination of Metformin hydrochloride (HCl), either alone or in combination [8].

The aim of the present work was to develop a Q - Absorption Ratio spectrophotometric method for simultaneous estimation of ANA and MET in combination. It is pertinent to note that, some of the published

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Methods enabled estimation of drugs in combination products containing two drugs via zero and first order derivative spectrophotometric method and HPLC however, so far, not any Q- Absorption ratio spectrophotometric method was reported for the same. Hence, to achieve this aim an accurate Q- Absorption ratio method has been developed and successfully applied to synthetic mixture.

2. Materials and methods

2.1. Apparatus

Instrument used was of Shimadzu UV-1600 series with a pair of 1 cm matched quartz cells. Software used was UV Probe 4.2 series. A digital analytical balance (Wenstar DA14-222) and ultrasonic sonicator (Equitron) were used in the study. Validated pipette of 1, 2, 5 mL; volumetric flasks of 10,100 mL; beakers of 100, 250, 500 mL were made up of Borosil glass.

2.2. Chemicals and reagents

Drug sample of ANA and MET were provided as a gift sample by Intas Pharmaceutical Pvt. Ltd., Ahmedabad, India. Bicilphase tablets (Metformin Hydrochloride 500mg) were purchased from local pharmacy store. Solvents like Distilled water were from E. Merck, Mumbai. All the chemicals reagents were of analytical Grade.

3. Methodology

The absorbance ratio method which obeys Beer’s law at all wavelength, the ratio of absorbance at any single wavelengths is constant value independent of concentration or path length. At 238 nm, solutions of both drugs of same concentration exhibit identical absorbance and consequently with zero difference. Such wavelengths of equal absorptivity of the two species are called isobestic or iso-absorptive points [23]. Q - Absorption ratio method uses ratio of absorbance at two selected wavelengths, one which is an iso-absorptive point and other being the $\lambda_{\text{max}}$ of one of two components. From overlay spectra of two drugs, it was evident that ANA and MET have an iso-absorptive point at 238 nm ($\lambda_1$). The second wavelength used was 233 nm ($\lambda_2$) of $\lambda_{\text{max}}$ of MET. ANA and MET showed considerable absorbance at both wavelengths (Figure 3).

The concentration of two drugs of mixture in 1:5 ratio at 238 nm and 233 nm can be calculated using following equation [23]:

$$C_x = \frac{Q_m - Q_y A_x}{Q_x - Q_y} \frac{A_1}{ax1}$$
$$C_y = \frac{Q_m - Q_x A_y}{Q_y - Q_x} \frac{A_2}{ay1}$$

where, $A_x$ and $A_y$ are absorbance of mixture at 238 nm and 233 nm;

$ax1 = A$ (Absorptivity, 1 %, 1 cm) of ANA at 238 nm (745.1)

$ay1 = A$ (1 %, 1 cm) of MET at 238 nm (669.4)

$ax2 = A$ (1 %, 1 cm) of ANA at 233 nm (549.8)

$ay2 = A$ (1 %, 1 cm) of MET at 233 nm (770.8);

$C_x$ and $C_y$ are the unknown concentration of Anagliptin and Metformin HCl respectively in sample solution.

$Q_m = A2/A1$, $Q_X = ax2/ ax1$ and $Q_Y = ay2/ay1$

3.1. Preparation of test solution for assay

3.1.1. Determination

Anagliptin/Metformin Hydrochloride is used in the ratio of 100/500mg for treatment of diabetes. Due to non-availability of product the
condition of mixture was simulated by using Biciphage tablets (Mefformin Hydrochloride 500mg) and API of ANA. Twenty tablets of Biciphage 500 mg tablets were weighed and triturated in a mortar pestle and powder equivalent to 500 mg of MET was taken into a 100 mL volumetric flask. To this flask, 100 mg of ANA API was added, to make concentration of ANA/MET in ratio of 1:5. The solution was adjusted to mark with distilled water to prepare test stock solutions correspond to 1000 μg/mL of ANA and 5000 μg/mL of MET, respectively. The contents of the flask were sonicated for 15 min to dissolve the active ingredients completely. The solution was filtered through a Whatman filter paper no. 41. From this 0.1 mL aliquot was transferred into a 10 mL volumetric flask and the volume was made up with distilled water. This test solution containing working concentrations of 2 μg/mL ANA and 10 μg/mL MET respectively, in mixture was analyzed for assay determination.

3.1.2. Preparation of calibration curve

From working standard solution of ANA (100 μg/mL), aliquots of 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 mL were transferred into series of 10 mL volumetric flask with the help of validated 1 mL pipette accurately and diluted up to mark with Distilled Water with the use of validated 10 mL pipette. This yielded solutions of 2, 4, 6, 8, 10 and 12 μg/mL of ANA. From working standard solution of MET (100 μg/mL), aliquots of 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mL were transferred into series of 10 mL volumetric flask with the help of validated 1 mL pipette accurately and diluted up to mark with Distilled Water with the use of validated 10 mL pipette. This yielded solutions of 5, 10, 15, 20, 25 and 30 μg/mL of MET.

4. Method validation

The proposed method was validated as per ICH guidelines Q2 (R1) [24].

4.1. Linearity and range

Linearity was studied by preparing standard solutions at 6 different concentrations. The linearity range for ANA and MET were found to be 2–12 μg/mL and 5–30 μg/mL respectively. For each solution, the absorbance of ANA and MET were measured at λ1 and λ2. The calibration curves of absorbance versus concentration were plotted. The linearity of absorbance responses versus concentrations was demonstrated by linear regression analysis.

4.2. Precision

The precision of the proposed method was assessed as repeatability, intra-day precision and inter-day precision. Repeatability was performed by applying six replicates of sample solution. For intermediate precision, Intraday and Interday precision was performed by determining corresponding responses of six replicates on same and different days for test solution containing ANA (2 μg/mL) and MET (10 μg/mL). The results were reported in terms of % RSD.

4.3. Accuracy

Recovery studies were carried out by standard addition method. A known amount of standard ANA (1, 2 and 3 μg/mL) and MET (5, 10 and 15 μg/mL) similar to 50%, 100% and 150% of the label claim were added to test solution of ANA (2 μg/mL) and MET (10 μg/mL).

Same study was carried out three times, at each level of recovery.

4.4. LOD and LOQ

The LOD and LOQ of the developed method were calculated from the calibration curve using equation, LOD = 3.3*σ/S and LOQ = 10*σ/S. Where, σ = the standard deviation of y-intercepts of regression lines of six calibration curves, S = the average of the slopes of six calibration curves.

5. Result and discussion

5.1. Linearity

| Sr No. | ANA at λ1 (μg/mL) | Absorbance± SD | %RSD | MET at λ1 (μg/mL) | Absorbance± SD | %RSD |
|--------|------------------|----------------|------|------------------|----------------|------|
| 1      | 2                | 0.122 ± 0.001  | 1.488| 5                | 0.349 ± 0.001  | 0.463|
| 2      | 4                | 0.224 ± 0.002  | 1.226| 10               | 0.767 ± 0.004  | 0.579|
| 3      | 6                | 0.323 ± 0.005  | 1.676| 15               | 1.140 ± 0.014  | 1.284|
| 4      | 8                | 0.419 ± 0.006  | 1.491| 20               | 1.527 ± 0.008  | 0.540|
| 5      | 10               | 0.522 ± 0.008  | 1.717| 15               | 1.920 ± 0.013  | 0.710|
| 6      | 12               | 0.628 ± 0.008  | 1.273| 30               | 2.339 ± 0.027  | 1.182|

*Average of six determinations.

Table 2. Linearity data of ANA and MET at λ2 as 233 nm.

| Sr No. | ANA at λ2 (μg/mL) | Absorbance± SD | %RSD | MET at λ2 (μg/mL) | Absorbance± SD | %RSD |
|--------|------------------|----------------|------|------------------|----------------|------|
| 1      | 2                | 0.164 ± 0.002  | 1.552| 5                | 0.308 ± 0.004  | 1.596|
| 2      | 4                | 0.303 ± 0.004  | 1.546| 10               | 0.675 ± 0.009  | 1.478|
| 3      | 6                | 0.442 ± 0.007  | 1.670| 15               | 1.020 ± 0.010  | 1.009|
| 4      | 8                | 0.571 ± 0.004  | 0.770| 20               | 1.340 ± 0.010  | 0.753|
| 5      | 10               | 0.704 ± 0.005  | 0.757| 15               | 1.735 ± 0.021  | 1.257|
| 6      | 12               | 0.867 ± 0.012  | 1.437| 30               | 2.078 ± 0.023  | 1.143|

*Average of six determinations.
The calibration curve obtained by the least square regression analysis between average absorbance and concentration showed linear relationship with a correlation coefficient $R^2$ nearer to 0.999 for ANA and MET at $\lambda_1$ and $\lambda_2$. The linear regression equation obtained were $y = 0.0693x + 0.0243$ and $y = 0.0502x + 0.0219$ for ANA at $\lambda_1$ and $\lambda_2$ respectively. The linear regression equation obtained were $y = 0.0706x - 0.0418$ and $y = \ldots$
Figure 7. Calibration curve of ANA at $\lambda_2 = 233$ nm.

Figure 8. Calibration curve of MET at $\lambda_1 = 238$ nm.

Figure 9. Calibration curve of MET at $\lambda_2 = 233$ nm.

| Concentration of Test solution (µg/mL) | Absorbance* ± SD | %RSD |
|---------------------------------------|------------------|------|
|                                       | ANA              | MET  | At $\lambda_1$ 238 nm | At $\lambda_2$ 233 nm | At $\lambda_1$ 238 nm | At $\lambda_2$ 233 nm |
| Repeatability 2                      | 0.831 ± 0.009    | 0.867 ± 0.009 | 1.161 | 1.147 |
| Intraday Precision 2                 | 0.890 ± 0.009    | 0.871 ± 0.010 | 1.192 | 1.241 |
| Interday Precision 2                 | 0.832 ± 0.011    | 0.880 ± 0.012 | 1.367 | 1.403 |

*Average of six determinations.
0.0788x - 0.0386 for MET at \( \lambda_1 \) and \( \lambda_2 \) respectively (Tables 1 and 2) (Figures 4, 5, 6, 7, 8, and 9).

5.2. Precision

The % RSD of repeatability was found to be 1.147 and 1.161 of test solution containing ANA 2 \( \mu g/mL \) and MET 10 \( \mu g/mL \). The % RSD of Intraday precision was found to be 1.241 and 1.192 at \( \lambda_1 \) and \( \lambda_2 \) respectively. The % RSD of Interday precision was found to be 1.403 and 1.367 at \( \lambda_1 \) and \( \lambda_2 \) respectively. Thus, confirming precision of the method (Table 3).

5.3. Accuracy

Accuracy of the method was confirmed by recovery study from marketed formulation at three level of standard addition method. Percentage recovery for ANA was in range of 100.42–101.83 %, while for MET, it was found to be in range of 99.94–101.63 % (Table 4).

5.4. LOD & LOQ

The LOD was calculated by standard formula as given in ICH guidelines was found to be 0.201383 \( \mu g/mL \) and 0.26216 \( \mu g/mL \) for ANA at \( \lambda_1 \) and \( \lambda_2 \) respectively. The LOD was found to be 0.32089 \( \mu g/mL \) and 0.16716 \( \mu g/mL \) for MET at \( \lambda_1 \) and \( \lambda_2 \) respectively. The LOQ was calculated by standard formulae as given in ICH guidelines was found to be 0.61025 \( \mu g/mL \) and 0.79442 \( \mu g/mL \) for ANA at \( \lambda_1 \) and \( \lambda_2 \) respectively. The LOQ was found to be 0.97242 \( \mu g/mL \) and 0.50654 \( \mu g/mL \) for MET at \( \lambda_1 \) and \( \lambda_2 \) respectively.

5.5. Analysis of ANA and MET in test solution

The developed methods was applied to sample solution of synthetic mixture. The % Assay of ANA and MET was 100.601% and 100.206 % respectively of the labelled amount (Figure 10, Table 5).

Table 4. Accuracy data of ANA and MET.

| Drug | Amount of Test Solution (\( \mu g/mL \)) | Amount of Standard added (\( \mu g/mL \)) | Absorbance* \( \pm \) SD | Total Amount Found (\( \mu g/mL \)) | Recovered amount (\( \mu g/mL \)) | % Recovery | % RSD |
|------|---------------------------------|---------------------------------|-----------------|-----------------|-----------------|----------|------|
| ANA  | 2 | 0 | 0.647 \( \pm \) 0.007 | 2.008 | — | 100.42 | 1.081 |
| MET  | 10 | 0 | 0.863 \( \pm \) 0.009 | 10.008 | — | 100.08 | 1.089 |
| ANA  | 2 | 1 | 0.985 \( \pm \) 0.011 | 3.054 | 1.054 | 101.83 | 1.195 |
| MET  | 10 | 5 | 1.297 \( \pm \) 0.015 | 15.032 | 5.032 | 100.21 | 1.204 |
| ANA  | 2 | 2 | 1.299 \( \pm \) 0.016 | 4.029 | 2.029 | 100.74 | 1.260 |
| MET  | 10 | 10 | 1.754 \( \pm \) 0.018 | 20.327 | 10.327 | 101.63 | 1.041 |
| ANA  | 2 | 3 | 1.632 \( \pm \) 0.027 | 5.062 | 3.063 | 101.26 | 1.673 |
| MET  | 10 | 15 | 2.156 \( \pm \) 0.023 | 24.986 | 14.986 | 99.94 | 1.071 |

*Average of three determinations.

Table 5. Analysis of Tablet formulation.

| Drug | Amount of drug Actual | Amount of drug Estimated | % Label claimed* \( \pm \) SD | % RSD |
|------|-----------------|-----------------|-----------------|------|
| ANA  | 2 | 2.012 | 100.601 \( \pm \) 1.193 | 1.193 |
| MET  | 10 | 10.02 | 100.206 \( \pm \) 1.287 | 1.287 |

*Average of six determinations.
Summary of validation parameters.

| Sr. No. | Parameter         | ANA (238 nm) | MET (233 nm) |
|---------|------------------|--------------|--------------|
|         |                  | \(\lambda_1\) | \(\lambda_2\) | \(\lambda_1\) | \(\lambda_2\) |
| 1       | Specificity      | Specific     | Specific     |              |              |
| 2       | Linearity Range  | 2-12 \(\mu\)g/mL | 5-30 \(\mu\)g/mL |              |              |
| 3       | Regression Line equation | \(y = 0.0693x + 0.0243\) | \(y = 0.0502x + 0.0219\) | \(y = 0.0706x - 0.0418\) | \(y = 0.0788x - 0.0386\) |
| 4       | Correlation Coefficient | \(R^2 = 0.999\) | \(R^2 = 0.9998\) | \(R^2 = 0.9995\) | \(R^2 = 0.9997\) |
| 5       | Precision        | \% RSD       | 1.161        | 1.47         |              |
|         | Repeatability    |              | 1.192        | 1.241        |              |
|         | Intraday Precision |              | 1.367        | 1.403        |              |
|         | Interday Precision |              |              |              |              |
| 6       | Accuracy (% Recovery) | 100.42–101.83 | 99.94–101.63 |              |              |
| 7       | LOD (\(\mu\)g/mL) | 0.201 \(\mu\)g/mL | 0.262 \(\mu\)g/mL | 0.320 \(\mu\)g/mL | 0.167 \(\mu\)g/mL |
| 8       | LOQ (\(\mu\)g/mL) | 0.610 \(\mu\)g/mL | 0.794 \(\mu\)g/mL | 0.972 \(\mu\)g/mL | 0.506 \(\mu\)g/mL |

6. Conclusion

The proposed spectrophotometric method is precise, specific, linear and accurate for the estimation of ANA and MET in synthetic mixture. The developed method is validated as per ICH guidelines Q2 R1. The method was successfully used for simultaneous estimation of both drugs in presence of each other.

Declarations

Author contribution statement

R.M. Hasmukhray: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.
A. Khodadiya and V.B. Patel: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

Acknowledgements

The authors are grateful to INTAS Pharmaceuticals, Ahmedabad for providing a gift sample of Anagliptin and Metformin. The authors are also thankful to Dr. Bhamini Chuadhary for providing guidance in the research work.

References

[1] Anagliptin tablet (Accessed on March, 2020), https://medical.kowa.co.jp/asset/item/24/35/7-pse_163.pdf.
[2] Anagliptin compound (Accessed on January, 2020), https://pubchem.ncbi.nlm.nih.gov/compound/44513473.
[3] H. Mohan, in: sixth ed. Textbook of Pathophysiology, Medical publishers Pvt Limited, 2005, pp. 818–828.
[4] K.D. Tripathi, in: sixth ed. Essential of Medical Pharmacology, Jaypee Brother Medical Publishers Ltd, 2008, pp. 254–274.
[5] V. Takeuchi, M. Namiki, Y. Kitahara, Safety, tolerability, pharmacokinetics and pharmacodynamics of E3024, a novel and selective Dipeptidyl peptidase-IV inhibitor, in healthy Japanese male subjects: rash development in men and its possible mechanism, Pharmacol. Pharm. 4 (2013) 663–678.
[6] P. Bhati, H. Panchal, Stability indicating chromatographic method development and validation for the simultaneous estimation of metformin HCl & Anagliptin in its synthetic mixture by HPLC, World J. Pharmaceut. Res. 6 (2017) 956–973.
[7] R. Majithia, J. Shah, Development and validation of analytical method for estimation of Anagliptin tablet dosage form by UV spectrophotometric method, International J. of Pharmacy and Technologies 6 (2015) 7765–7771.
[8] S. Shah, D. Madeshwari, First order derivative spectrophotometric method for simultaneous estimation of Anagliptin and metformin HCl in bulk and synthetic mixture, J. Global Trends Pharmaceut. Sci. 6 (2015) 2925–2929.
[9] A. Patil, A. Shirkhedkar, Development and validation of five simple UV-spectrophotometry methods for estimation of Anagliptin in bulk and in-house tablets, Pharm. Methods 7 (2016) 127–131.
[10] C. Pandya, S. Raiput, Stress degradation studies of Anagliptin, development of validated stability indicating method, degradation kinetics study, identification and isolation of degradation products, Chromatographia, An Int. J. Sep. sci. (2018) 1–21.
[11] S. Baira, D. Sigalapalli, N. Bathini, LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of Anagliptin, J. Pharmaceut. Biomed. Anal. 159 (2018) 92–99.
[12] Metformin hydrochloride compound (Accessed on January, 2020), https://www.drugbank.ca/drugs/DB00331.
[13] W. Roger, in: fourth ed. Cate W, Clinical Pharmacy & Therapeutics, Churchill Livingstone Elsevier, 2008, pp. 685–710.
[14] H. Rang, M. Dale, in: seventh ed. Rang & Dale’s Pharmacology, Elsevier Publication, 2012, pp. 402–408.
[15] Ip, The Indian Pharmacopoeia Commission, Ghaziabad, India, 2014.
[16] Bp, The British Pharmacopoeia, Medicine & Healthcare Products Regulatory Agency, London, 2010.
[17] USP, the United States Pharmacopoeia Convention, Rockville, MD, USA, 2010.
[18] C. Parle, A. Parle, Development and validation of spectrophotometric method for simultaneous estimation of metformin hydrochloride and Alogliptin benzoate in bulk drugs and combined dosage forms, Der Pharma Chem. 6 (2014) 303–311.
[19] J. Chopade, S. Deshpande, S. Shah, Simultaneous estimation of metformin HCl and glipizide by Q- analysis method, Int. J. Pharm. Res. Sch. 2 (2013) 66–73.
[20] P. Umamathi, J. Ayyappan, Quantitative determination of metformin hydrochloride in tablet formulation containing crosccarmellose sodium as disintegrant by HPLC and UV spectrophotometry, Trop. J. Pharmaceut. Res. 11 (2012) 107–116.
[21] M. Kar, P. Chaudhary, HPLC method for estimation of metformin HCl in formulated microspheres and tablet dosage form, Indian J. Pharmaceut. Sci. 71 (2009) 318–320.
[22] C. Reddy, G. Mubeen, M. Pal, HPTLC method for estimation of metformin hydrochloride, Biomed. & Pharmacol. J. 1 (2008) 445–448.
[23] A.G. Davidson, A.H. Beckett, J.B. Stenlake, in: fourth ed. Practical Pharmaceutical Chemistry, CBS Publisher, New Delhi, 2002, pp. 286–296.
[24] ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2 (R1), International Conference on Harmonization, Geneva, Switzerland, 2005, pp. 1–12.